Measuring ctDNA levels before radiotherapy predicted PFS and overall survival, and can help determine the patients most likely to benefit from consolidation radiotherapy vs systemic therapy.
With the neoadjuvant regimen of pembrolizumab added to dabrafenib and trametinib, survival in BRAF-mutated forms of the highly aggressive cancer can go from months to more than 5 years.